Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma

Cancer Letters

Volumn 282, Issue 2, 2009, Pages 205-213

  Xu, Gang ^a   Xiang, Cui Qin ^b   Lu, Ye ^b   Kang, Xiao Nan ^c   Liao, Ping ^b   Ding, Qiang ^a   Zhang, Yuan Fang ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; Proteomics; Renal cell carcinoma; SELDI TOF MS

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROTEIN SUBUNIT; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION;

ADULT; AGED; CARCINOMA, RENAL CELL; DECISION TREES; ENDOPLASMIC RETICULUM; EUKARYOTIC INITIATION FACTOR-2B; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EUKARYOTA;

EID: 67649973822     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.017     Document Type: Article

References (29)

1. Tunuguntla H.S., and Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J. Urol. 179 (2008) 2096-2102
2. Weiss R.H., and Lin P.Y. Kidney cancer: identification of novel targets for therapy. Kidney Int. 69 (2006) 224-232
3. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J. Urol. 166 (2001) 1611-1623
4. Remzi M., Katzenbeisser D., Waldert M., Klingler H.C., Susani M., Memarsadeghi M., Heinz-Peer G., Haitel A., Herwig R., and Marberger M. Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int. 99 (2007) 1002-1006
5. Pahernik S., Ziegler S., Roos F., Melchior S.W., and Thuroff J.W. Small renal tumors: correlation of clinical and pathological features with tumor size. J. Urol. 178 (2007) 414-417 (discussion 416-417)
6. Matt P., Fu Z., Fu Q., and Van Eyk J.E. Biomarker discovery: proteome fractionation and separation in biological samples. Physiol. Genomics 33 (2008) 12-17
7. Hutchens T.W., and Yip T.T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 7 (1993) 576-580
8. Poon T.C. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 4 (2007) 51-65
9. Hara T., Honda K., Ono M., Naito K., Hirohashi S., and Yamada T. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J. Urol. 174 (2005) 1213-1217
10. Junker K., Gneist J., Melle C., Driesch D., Schubert J., Claussen U., and Von Eggeling F. Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics. Int. J. Mol. Med. 15 (2005) 285-290
11. Won Y., Song H.J., Kang T.W., Kim J.J., Han B.D., and Lee S.W. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3 (2003) 2310-2316
12. Wu D.L., Wang W.J., Guan M., Jin S.B., Jin C.R., and Zhang Y.F. Application of SELDI-TOF-MS technique in screening urine biomarkers from patients with renal cell carcinoma. Natl. Med. J. China 84 (2004) 1092-1095
13. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. New Engl. J. Med. 335 (1996) 865-875
14. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
15. Hyman E., Kauraniemi P., Hautaniemi S., Wolf M., Mousses S., Rozenblum E., Ringner M., Sauter G., Monni O., Elkahloun A., Kallioniemi O.P., and Kallioniemi A. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 62 (2002) 6240-6245
16. Zhou W. Mapping genetic alterations in tumors with single nucleotide polymorphisms. Curr. Opin. Oncol. 15 (2003) 50-54
17. Rogers M.A., Clarke P., Noble J., Munro N.P., Paul A., Selby P.J., and Banks R.E. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63 (2003) 6971-6983
18. Abbott C.M., and Proud C.G. Translation factors: in sickness and in health. Trends. Biochem. Sci. 29 (2004) 25-31
19. Pavitt G.D., Ramaiah K.V., Kimball S.R., and Hinnebusch A.G. eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange. Genes Dev. 12 (1998) 514-526
20. Zhan K., Narasimhan J., and Wek R.C. Differential activation of eIF2 kinases in response to cellular stresses in Schizosaccharomyces pombe. Genetics 168 (2004) 1867-1875
21. Fritsch R.M., Schneider G., Saur D., Scheibel M., and Schmid R.M. Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation. J. Biol. Chem. 282 (2007) 22551-22562
22. Kline C.L., Schrufer T.L., Jefferson L.S., and Kimball S.R. Glucosamine-induced phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 is mediated by the protein kinase R-like endoplasmic-reticulum associated kinase. Int. J. Biochem. Cell Biol. 38 (2006) 1004-1014
23. Scheuner D., Patel R., Wang F., Lee K., Kumar K., Wu J., Nilsson A., Karin M., and Kaufman R.J. Double-stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 mediates apoptosis. J. Biol. Chem. 281 (2006) 21458-21468
24. Jeffrey I.W., Elia A., Bornes S., Tilleray V.J., Gengatharan K., and Clemens M.J. Interferon-alpha induces sensitization of cells to inhibition of protein synthesis by tumour necrosis factor-related apoptosis-inducing ligand. FEBS J. 273 (2006) 3698-3708
25. Balachandran S., Roberts P.C., Brown L.E., Truong H., Pattnaik A.K., Archer D.R., and Barber G.N. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13 (2000) 129-141
26. Balachandran S., and Barber G.N. PKR in innate immunity, cancer, and viral oncolysis. Methods Mol. Biol. 383 (2007) 277-301
27. Nowis D., McConnell E.J., Dierlam L., Palamarchuk A., Lass A., and Wojcik C. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. Int. J. Cancer 121 (2007) 431-441
28. Adachi H., Majima S., Kon S., Kobayashi T., Kajino K., Mitani H., Hirayama Y., Shiina H., Igawa M., and Hino O. Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis. Oncogene 23 (2004) 3495-3500
29. Sun G.D., Kobayashi T., Abe M., Tada N., Adachi H., Shiota A., Totsuka Y., and Hino O. The endoplasmic reticulum stress-inducible protein Niban regulates eIF2alpha and S6K1/4E-BP1 phosphorylation. Biochem. Biophys. Res. Commun. 360 (2007) 181-187